valcyte医保给报销吗？

Will medical insurance reimburse me? The editor below will answer this question for you. Valcyte, branded as Valcyte, is an antiviral drug used to treat patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis, and to prevent CMV infection in high-risk solid organ transplant patients.

The recommended dose of valcyte for the treatment of induction of cytomegalovirus retinitis is 900 mg (two 450 mg tablets) twice daily for 21 days. Maintenance: After induction therapy, or in adult patients with inactive cytomegalovirus retinitis, the recommended dose is 900 mg orally once daily. Use with caution in patients with impaired renal function; dosage needs to be adjusted under physician advice.

In May 2001, the US FDA approved the market. Valcyte is clinically used to treat acute retinitis caused by CMV infection in patients with acquired immunodeficiency syndrome. In May 2003, its indications were expanded. Valcyte is used to prevent and treat secondary CMV infection in organ transplant recipients.

In August 2006, valcyte was launched in China with a specification of 450mg*60 tablets/box and a relatively high price of 16,500$/box. Due to the high price of the original drug, many patients are asking about the medical insurance reimbursement of valcyte. Unfortunately, although valcyte has been launched in my country, valcyte has not been included in my country's medical insurance catalogue, which means that patients cannot be reimbursed by medical insurance, which is a bit unaffordable for patients with average economic levels. However, there is currently the most cost-effective valcyte on the market in India. According to the editor of Medical Companion Travel, Roche’s (valgancilovir hydrochloride tablets, valgansiklovir) 450mg*60 tablets are sold in Indian pharmacies for about RMB 5,500. Patients can choose to go to Indian pharmacies to purchase in person, or contact Medical Companion Travel Service for assistance in purchasing.